Drugs / Forimtamig
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04557150 | Nov 2020 → Mar 2026 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06055075 | Dec 2023 → Jul 2025 | refractory plasma cell neoplasm | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Forimtamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04557150 ↗ |
| Known as | RG-6234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314680 ↗ |
| Known as | RO-7425781 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314680 ↗ |
| Known as | Theme 70238 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314680 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314680 ↗ |
| Route | Intravenous | “forimtamig as intravenous (IV) infusion” NCT04557150 ↗ |
| Target | GPRC5D | “GPRC5D-targeting” PMID 39476124 ↗ Jan 2025 |